BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, announced the launch of two new compound libraries, targeting Family C GPCR’s and protein-protein interactions.
BioClinica, Inc., a global provider of clinical trial services, announced its financial results for the fourth quarter and year ended December 31, 2010. Service revenues were $16.5 million as compared with $14.9 million for the same period 2009.
NSF International, an independent public health organization, has acquired Pharmalytica Services, a pharmaceutical contract laboratory that provides a full range of GLP & GMP analytical services to the pharmaceutical and biotechnology industry.
Polaris Group announces the enrollment of its first patient in a Phase 2 clinical trial, sponsored by The Ludwig Institute for Cancer Research, evaluating ADI-PEG 20 in the treatment of small cell lung cancer.
Acacia Pharma has initiated a dose-escalating, Phase 2a proof-of-concept study of APD421, is an intravenous formulation of a currently marketed dopamine D2 antagonist for the new use of prevention and treatment of nausea & vomiting.
Abnormal heart rate turbulence is associated with an increased risk of heart disease death in otherwise low-risk older individuals, according to a study funded by the National Heart, Lung, and Blood Institute.
Scientists today agree that there are five molecules that are known to affect or cause Alzheimer's disease, which plagues an estimated five million Americans. The potency of these molecules is linked to environmental factors such as diet and lifestyle.
Scientists have developed new synthetic molecules as models to study the structural and functional role of the proline residue and tetrapeptide sequence important for the regulation of cancer cell apoptosis by the XIAP protein.
Recently published findings present possible new opportunities for developing organism-specific drugs, which target the pathogen that causes tuberculosis but leave other microorganisms, which are beneficial to us, untouched.
Ligand Pharmaceuticals Inc. reported a smaller fourth-quarter profit compared to a year ago, when one-time payments boosted its revenue. Ligand said its net income fell to $2.4 million.
A new study suggests a way to help men with early, low-risk prostate cancer avoid being overtreated for a disease that in most cases will never threaten their lives. It found that a drug can slow the growth of these tumors in men who opt to be monitored instead of having treatment right away.
A unit of Johnson & Johnson has recalled 70,000 syringes of its antipsychotic drug Invega Sustenna after finding that some of the pre-filled syringes may have cracks which possibly could affect the drug's sterility.
Novo Nordisk A/S says it has been subpoenaed by the U.S. Attorney for the District of Massachusetts in an investigation of how the Danish pharmaceutical company markets three diabetes drugs.
French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the market in lucrative drugs for rare genetic disorders.
The development of monoclonal antibodies as therapies and as diagnostics has made tremendous advances since the approval of the first therapeutic mAb 25 years ago. New technologies have enabled the synthesis of fully human mAbs.